The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
Official Title: A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
Study ID: NCT02099058
Brief Summary: This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in participants with advanced solid tumors likely to express c-Met. Enrollment is closed for the monotherapy arms, Arm A, and Arm D.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Scottsdale Healthcare /ID# 123761, Scottsdale, Arizona, United States
City of Hope /ID# 153759, Duarte, California, United States
University of California, Los Angeles /ID# 148295, Los Angeles, California, United States
UC Irvine /ID# 165107, Orange, California, United States
University of California, Davis Comprehensive Cancer Center /ID# 129805, Sacramento, California, United States
Univ of Colorado Cancer Center /ID# 123759, Aurora, Colorado, United States
The University of Chicago Medical Center /ID# 136995, Chicago, Illinois, United States
Ingalls Memorial Hosp /ID# 165876, Harvey, Illinois, United States
Massachusetts General Hospital /ID# 129804, Boston, Massachusetts, United States
Dana-Farber Cancer Institute /ID# 168782, Boston, Massachusetts, United States
Henry Ford Health System /ID# 149857, Detroit, Michigan, United States
Herbert Herman Cancer Center /ID# 149858, Lansing, Michigan, United States
Washington University-School of Medicine /ID# 143798, Saint Louis, Missouri, United States
Summit Medical Group-Florham Park /ID# 217651, Florham Park, New Jersey, United States
Montefiore Medical Park at Eastchester /ID# 218445, Bronx, New York, United States
Northwell Health - Monter Cancer Center /ID# 218170, Lake Success, New York, United States
Duke Cancer Center /ID# 123763, Durham, North Carolina, United States
Tennessee Oncology, PLLC /ID# 129802, Nashville, Tennessee, United States
Mary Crowley Cancer Research /ID# 123760, Dallas, Texas, United States
University of Texas MD Anderson Cancer Center /ID# 154648, Houston, Texas, United States
Virginia Cancer Specialists - Fairfax /ID# 165708, Fairfax, Virginia, United States
Universitair Ziekenhuis Antwerpen /ID# 170118, Edegem, Antwerpen, Belgium
Tampere University Hospital /ID# 165065, Tampere, Pirkanmaa, Finland
AP-HM - Hopital de la Timone /ID# 151570, Marseille CEDEX 05, Bouches-du-Rhone, France
Institut Gustave Roussy /ID# 132747, Villejuif Cedex, Val-de-Marne, France
Duplicate_Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRCCS /ID# 164077, Meldola, Emilia-Romagna, Italy
National Cancer Center Hospital East /ID# 217570, Kashiwa-shi, Chiba, Japan
National Cancer Center Hospital /ID# 217571, Chuo-ku, Tokyo, Japan
The Catholic University of Korea, ST. Vincent's Hospital /ID# 233378, Suwon, Gyeonggido, Korea, Republic of
Yonsei University Health System Severance Hospital /ID# 217333, Seoul, Seoul Teugbyeolsi, Korea, Republic of
Asan Medical Center /ID# 217334, Seoul, , Korea, Republic of
Radboud Universitair Medisch Centrum /ID# 246908, Nijmegen, Gelderland, Netherlands
China Medical University Hospital /ID# 217494, Taichung, , Taiwan
National Cheng Kung University Hospital /ID# 167175, Tainan, , Taiwan
National Taiwan University Hospital /ID# 167173, Taipei City, , Taiwan
Taipei Veterans General Hosp /ID# 217392, Taipei, , Taiwan
Name: ABBVIE INC.
Affiliation: AbbVie
Role: STUDY_DIRECTOR